KWM
VKTX icon

Kingsview Wealth Management’s Viking Therapeutics VKTX Stock Holding History

Kingsview Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1M Buy
25,674
+3,699
+17% +$119K 0.01% 753
2026
Q1 		$715K Buy
21,975
+5,318
+32% +$171K 0.01% 780
2025
Q4 		$586K Buy
+16,657
New +$590K 0.01% 793
2024
Q4 		– Sell
-3,445
Closed -$218K – 1191
2024
Q3 		$218K Buy
+3,445
New +$202K ﹤0.01% 1003

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Kingsview Wealth Management's VKTX Position: Q2 2026 in Review

Kingsview Wealth Management increased its Viking Therapeutics (VKTX) stake by 17% in Q2 2026, buying an estimated $119K and bringing the position to 25,674 shares worth $1M. The position accounts for 0.01% of the portfolio, ranked #753.

Kingsview Wealth Management first reported a position in VKTX in Q3 2024 and has held it in 4 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Kingsview Wealth Management held 25,674 shares of Viking Therapeutics worth $1M as of Q2 2026.
  • Kingsview Wealth Management bought 3,699 Viking Therapeutics shares in Q2 2026, an estimated $119K.
  • Viking Therapeutics made up 0.01% of Kingsview Wealth Management's portfolio in Q2 2026, its #753 holding.
  • Kingsview Wealth Management first reported a position in Viking Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Kingsview Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.